nivolumab,ipilimumab,sunitinib,pazopanib
novartis,bms,pfizer
['rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bionikk']
updated os and efficacy results from the phase 2 #bionikk trial of second-line treatment in patients with #mrcc were presented at #gu2023. this multicenter, noncomparative, phase 2 trial showed promising orr and progression-free survival. read more: 
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and important advancements in the genitourinary oncology field.